Dopamine inhibits growth hormone and prolactin secretion in the human newborn

F. De Zegher, G. Van den Berghe, H. Devlieger, E. Eggermont, Johannes D Veldhuis

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Dopamine is frequently used in neonatal intensive care for its vasopressor, renal vasodilating, and cardiac inotropic properties. The effect of i.v. dopamine infusion on neonatal pituitary hormone secretion is currently unknown. We observed strikingly low serum concentrations of growth hormone (GH) and prolactin (PRL) during a therapeutic, standardized, isovolumetric, partial exchange transfusion (blood sampling every 20 min for 6 h) in two polycythemic neonates requiring intensive therapy, including continuous dopamine infusion. In addition, the secretion of GH and PRL was studied in three neonates with symptomatic polycythemia (gestational age 34- 38 wk; birth weight 2110-2530 g; postnatal age 10-30 h) during a partial exchange transfusion, including an intervening dopamine infusion (8 μg/kg/min i.v. for 2 h). The GH and PRL profiles were evaluated by deconvolution analysis. Initially, the three newborns exhibited high- amplitude, pulsatile GH secretion and continuously elevated PRL release. During the dopamine infusion, GH secretion was virtually abolished and PRL release was reduced by at least 50%. Dopamine withdrawal was associated with a rebound release of GH and PRL. Finally, serum GH and PRL concentrations were studied in nine nonpolycythemic newborns (gestational age 31-40 wk; birth weight 1680-4000 g; postnatal age 2-28 d) at the end of a prolonged dopamine infusion (3-5 μg/kg/min i.v. for 2-27 d). Within 2 h after dopamine withdrawal, GH and PRL levels increased a median 3-fold and 10-fold respectively. These data concord to indicate that dopamine is a potent inhibitor of GH and PRL secretion in the human newborn.

Original languageEnglish (US)
Pages (from-to)642-645
Number of pages4
JournalPediatric Research
Volume34
Issue number5
StatePublished - 1993
Externally publishedYes

Fingerprint

Prolactin
Growth Hormone
Dopamine
Birth Weight
Gestational Age
Neonatal Intensive Care
Polycythemia
Pituitary Hormones
Serum
Blood Transfusion
Kidney
Therapeutics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

De Zegher, F., Van den Berghe, G., Devlieger, H., Eggermont, E., & Veldhuis, J. D. (1993). Dopamine inhibits growth hormone and prolactin secretion in the human newborn. Pediatric Research, 34(5), 642-645.

Dopamine inhibits growth hormone and prolactin secretion in the human newborn. / De Zegher, F.; Van den Berghe, G.; Devlieger, H.; Eggermont, E.; Veldhuis, Johannes D.

In: Pediatric Research, Vol. 34, No. 5, 1993, p. 642-645.

Research output: Contribution to journalArticle

De Zegher, F, Van den Berghe, G, Devlieger, H, Eggermont, E & Veldhuis, JD 1993, 'Dopamine inhibits growth hormone and prolactin secretion in the human newborn', Pediatric Research, vol. 34, no. 5, pp. 642-645.
De Zegher F, Van den Berghe G, Devlieger H, Eggermont E, Veldhuis JD. Dopamine inhibits growth hormone and prolactin secretion in the human newborn. Pediatric Research. 1993;34(5):642-645.
De Zegher, F. ; Van den Berghe, G. ; Devlieger, H. ; Eggermont, E. ; Veldhuis, Johannes D. / Dopamine inhibits growth hormone and prolactin secretion in the human newborn. In: Pediatric Research. 1993 ; Vol. 34, No. 5. pp. 642-645.
@article{02a773cf8aff4bfa9f5c4773aebdde16,
title = "Dopamine inhibits growth hormone and prolactin secretion in the human newborn",
abstract = "Dopamine is frequently used in neonatal intensive care for its vasopressor, renal vasodilating, and cardiac inotropic properties. The effect of i.v. dopamine infusion on neonatal pituitary hormone secretion is currently unknown. We observed strikingly low serum concentrations of growth hormone (GH) and prolactin (PRL) during a therapeutic, standardized, isovolumetric, partial exchange transfusion (blood sampling every 20 min for 6 h) in two polycythemic neonates requiring intensive therapy, including continuous dopamine infusion. In addition, the secretion of GH and PRL was studied in three neonates with symptomatic polycythemia (gestational age 34- 38 wk; birth weight 2110-2530 g; postnatal age 10-30 h) during a partial exchange transfusion, including an intervening dopamine infusion (8 μg/kg/min i.v. for 2 h). The GH and PRL profiles were evaluated by deconvolution analysis. Initially, the three newborns exhibited high- amplitude, pulsatile GH secretion and continuously elevated PRL release. During the dopamine infusion, GH secretion was virtually abolished and PRL release was reduced by at least 50{\%}. Dopamine withdrawal was associated with a rebound release of GH and PRL. Finally, serum GH and PRL concentrations were studied in nine nonpolycythemic newborns (gestational age 31-40 wk; birth weight 1680-4000 g; postnatal age 2-28 d) at the end of a prolonged dopamine infusion (3-5 μg/kg/min i.v. for 2-27 d). Within 2 h after dopamine withdrawal, GH and PRL levels increased a median 3-fold and 10-fold respectively. These data concord to indicate that dopamine is a potent inhibitor of GH and PRL secretion in the human newborn.",
author = "{De Zegher}, F. and {Van den Berghe}, G. and H. Devlieger and E. Eggermont and Veldhuis, {Johannes D}",
year = "1993",
language = "English (US)",
volume = "34",
pages = "642--645",
journal = "Pediatric Research",
issn = "0031-3998",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Dopamine inhibits growth hormone and prolactin secretion in the human newborn

AU - De Zegher, F.

AU - Van den Berghe, G.

AU - Devlieger, H.

AU - Eggermont, E.

AU - Veldhuis, Johannes D

PY - 1993

Y1 - 1993

N2 - Dopamine is frequently used in neonatal intensive care for its vasopressor, renal vasodilating, and cardiac inotropic properties. The effect of i.v. dopamine infusion on neonatal pituitary hormone secretion is currently unknown. We observed strikingly low serum concentrations of growth hormone (GH) and prolactin (PRL) during a therapeutic, standardized, isovolumetric, partial exchange transfusion (blood sampling every 20 min for 6 h) in two polycythemic neonates requiring intensive therapy, including continuous dopamine infusion. In addition, the secretion of GH and PRL was studied in three neonates with symptomatic polycythemia (gestational age 34- 38 wk; birth weight 2110-2530 g; postnatal age 10-30 h) during a partial exchange transfusion, including an intervening dopamine infusion (8 μg/kg/min i.v. for 2 h). The GH and PRL profiles were evaluated by deconvolution analysis. Initially, the three newborns exhibited high- amplitude, pulsatile GH secretion and continuously elevated PRL release. During the dopamine infusion, GH secretion was virtually abolished and PRL release was reduced by at least 50%. Dopamine withdrawal was associated with a rebound release of GH and PRL. Finally, serum GH and PRL concentrations were studied in nine nonpolycythemic newborns (gestational age 31-40 wk; birth weight 1680-4000 g; postnatal age 2-28 d) at the end of a prolonged dopamine infusion (3-5 μg/kg/min i.v. for 2-27 d). Within 2 h after dopamine withdrawal, GH and PRL levels increased a median 3-fold and 10-fold respectively. These data concord to indicate that dopamine is a potent inhibitor of GH and PRL secretion in the human newborn.

AB - Dopamine is frequently used in neonatal intensive care for its vasopressor, renal vasodilating, and cardiac inotropic properties. The effect of i.v. dopamine infusion on neonatal pituitary hormone secretion is currently unknown. We observed strikingly low serum concentrations of growth hormone (GH) and prolactin (PRL) during a therapeutic, standardized, isovolumetric, partial exchange transfusion (blood sampling every 20 min for 6 h) in two polycythemic neonates requiring intensive therapy, including continuous dopamine infusion. In addition, the secretion of GH and PRL was studied in three neonates with symptomatic polycythemia (gestational age 34- 38 wk; birth weight 2110-2530 g; postnatal age 10-30 h) during a partial exchange transfusion, including an intervening dopamine infusion (8 μg/kg/min i.v. for 2 h). The GH and PRL profiles were evaluated by deconvolution analysis. Initially, the three newborns exhibited high- amplitude, pulsatile GH secretion and continuously elevated PRL release. During the dopamine infusion, GH secretion was virtually abolished and PRL release was reduced by at least 50%. Dopamine withdrawal was associated with a rebound release of GH and PRL. Finally, serum GH and PRL concentrations were studied in nine nonpolycythemic newborns (gestational age 31-40 wk; birth weight 1680-4000 g; postnatal age 2-28 d) at the end of a prolonged dopamine infusion (3-5 μg/kg/min i.v. for 2-27 d). Within 2 h after dopamine withdrawal, GH and PRL levels increased a median 3-fold and 10-fold respectively. These data concord to indicate that dopamine is a potent inhibitor of GH and PRL secretion in the human newborn.

UR - http://www.scopus.com/inward/record.url?scp=0027452513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027452513&partnerID=8YFLogxK

M3 - Article

C2 - 8284103

AN - SCOPUS:0027452513

VL - 34

SP - 642

EP - 645

JO - Pediatric Research

JF - Pediatric Research

SN - 0031-3998

IS - 5

ER -